Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in TA-TMA After HSCT
2021-003157-27Phase 2Active
- Sponsor
- Sobi
- Start
- Oct 2021
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegcetacoplan in transplant-associated thrombotic microangiopathy (TA-TMA) and thrombotic microangiopathies (TMA), sponsored by Sobi. Primary endpoint: Pegcetacoplan pharmacokinetics. Started Oct 2021; status: active.
02
Drugs
pegcetacoplan
03
Conditions
transplant-associated thrombotic microangiopathy (TA-TMA)thrombotic microangiopathies (TMA)
Beyond the preview
Go deeper on 2021-003157-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003157-27.